The prevalence and burden of arthritis

Reginster, JY

doi:10.1093/rheumatology/41.suppl_1.3

Cited by 221 publications

(104 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The clinical need for bone replacement is expected to increase, due in part to the substantial rise in the elderly population of the western world [1,2]. Currently, close to 1 million bone grafts are performed each year for the purpose of skeletal augmentation [3][4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Silk based biomaterials to heal critical sized femur defects

Meinel

Betz

Fajardo

et al. 2006

Bone

219

182

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Silk based biomaterials to heal critical sized femur defects

Meinel

Betz

Fajardo

et al. 2006

Bone

219

182

View full text Add to dashboard Cite

“…Degenerative joint disease is a chronic debilitating condition affecting 43 million Americans at an estimated cost of $60 billion per year [18]. Although some patients should be managed conservatively with medical treatment, many will face considerable disability from progressive loss of hip or knee function.…”

Section: Introductionmentioning

confidence: 99%

Utilization of Elective Hip and Knee Arthroplasty by Age and Payer

Matlock

Earnest

Epstein³

2008

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Elective joint arthroplasty improves the quality of life for patients with severe arthritis. In the United States, utilization of services varies with insurance status. We asked the following questions: (1) Is there an increase in the utilization of elective hip and knee arthroplasty after age 65? (2) Does the difference in utilization between the insured and general populations decrease at age 65 (the age at which Medicare provides near universal coverage)? (3) Does Medicare become the primary payer of elective hip and knee arthroplasty after the age of 65? We used the National Inpatient Sample to identify patients and payers of elective hip and knee arthroplasties by age. We analyzed these data using regression models. At age 65, there was an upward shift in the incidence of arthroplasties in the general and the insured populations and the difference between these two populations decreased. Medicare was the primary payer for the majority of arthroplasties after age 65. We conclude at age 65 the following occurs: (1) utilization of elective joint arthroplasty increases; (2) the difference between the insured population and the general population decreases; and (3) Medicare becomes the primary payer of arthroplasties.

show abstract

“…1 The prevalence of OA is high and expected to increase in the coming years. 2 Results of epidemiologic researches indicate that the incidence of symptomatic OA is about 8 -9% in China. 3,4 OA is a multifactorial disorder in which aging, genetic, hormonal and mechanical factors are major contributors to its onset and progression, but the molecular mechanism underlying the cartilage degeneration is still largely unknown.…”

Section: Introductionmentioning

confidence: 99%

Mutation analysis of the Smad3 gene in human osteoarthritis

Yao

Wang

et al. 2003

Eur J Hum Genet

View full text Add to dashboard Cite

Osteoarthritis (OA) is the most common joint disease worldwide. Recent studies have shown that targeted disruption of Smad3 in mouse results in OA. To reveal the possible association between the Smad3 gene mutation and human OA, we employed polymerase chain reaction-single strand conformation polymorphism and sequencing to screen mutations in all nine exons of the Smad3 gene in 32 patients with knee OA and 50 patients with only bone fracture. A missense mutation of the Smad3 gene was found in one patient. The single base mutation located in the linker region of the SMAD3 protein was A-T change in the position 2 of codon 197 and resulted in an asparagine to isoleucine amino-acid substitution. The expressions of matrix metalloproteinase 2 (MMP-2) and MMP-9 in sera of the patient carrying the mutation were higher than other OA patients and controls. This is the first report showing that the Smad3 gene mutations could be associated with the pathogenesis of human OA.

show abstract

The prevalence and burden of arthritis

Cited by 221 publications

References 0 publications

Silk based biomaterials to heal critical sized femur defects

Silk based biomaterials to heal critical sized femur defects

Utilization of Elective Hip and Knee Arthroplasty by Age and Payer

Mutation analysis of the Smad3 gene in human osteoarthritis

Contact Info

Product

Resources

About